Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EphA5/MMAE antibody-drug conjugate MBRC-101

An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the tyrosine kinase receptor ephrin type-A receptor 5 (EPH receptor A5; EphA5) and conjugated, via a protease-cleavable linker, to the auristatin derivative and microtubule disrupting agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of anti-EphA5/MMAE ADC MBRC-101, the monoclonal antibody moiety targets and binds to EphA5 expressed on tumor cells. Upon binding, internalization, and proteolytic cleavage, MMAE is released. MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. This induces cell death in EphA5-expressing cancer cells. EphA5, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in axonal guidance during embryonic development, is overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-EphA5 ADC MBRC-101
anti-EphA5/MMAE ADC MBRC-101
Code name:MBRC 101
MBRC-101
MBRC101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search